Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash from Operations (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Cash from Operations data on record, last reported at 14755000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 61.36% year-over-year to 14755000.0; the TTM value through Dec 2025 reached 54122000.0, down 48.92%, while the annual FY2025 figure was 54122000.0, 48.92% down from the prior year.
  • Cash from Operations reached 14755000.0 in Q4 2025 per PLSE's latest filing, down from 13039000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6570000.0 in Q1 2023 and bottomed at 16366000.0 in Q2 2021.
  • Average Cash from Operations over 5 years is 11230800.0, with a median of 11159500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: crashed 106.15% in 2021, then surged 57.87% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 12694000.0 in 2021, then skyrocketed by 37.25% to 7965000.0 in 2022, then increased by 14.85% to 6782000.0 in 2023, then crashed by 34.83% to 9144000.0 in 2024, then tumbled by 61.36% to 14755000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 14755000.0 in Q4 2025, 13039000.0 in Q3 2025, and 12807000.0 in Q2 2025.